Dr Reddy's Laboratories Reports Robust Q4 Performance with 21% Profit Surge

Dr Reddy's Laboratories announced a notable 21% rise in its consolidated net profit for the March quarter, totaling Rs 1,587 crore. The pharmaceutical giant cited robust sales performance across key markets, including the US and India, as the driving force behind this growth.

In comparison to the previous fiscal period's net profit of Rs 1,307 crore, the latest figures highlight significant progress for the Hyderabad-based firm. Revenue for the same quarter escalated to Rs 8,506 crore from Rs 7,083 crore year-on-year, as detailed in the company's regulatory filing.

Looking ahead, Dr Reddy's is committed to expanding its core businesses through effective portfolio management and operational excellence. The firm also aims to explore strategic partnerships and growth through acquisitions. The board has recommended a final dividend of Rs 8 per share for FY25 and approved the re-appointment of G V Prasad as a key executive.

(With inputs from agencies.)